caffeine has been researched along with Infant, Newborn, Diseases in 40 studies
Infant, Newborn, Diseases: Diseases of newborn infants present at birth (congenital) or developing within the first month of birth. It does not include hereditary diseases not manifesting at birth or within the first 30 days of life nor does it include inborn errors of metabolism. Both HEREDITARY DISEASES and METABOLISM, INBORN ERRORS are available as general concepts.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Apnea of prematurity (AOP) is one of the common diseases in preterm infants." | 9.22 | [Recent research on gene polymorphisms related to caffeine therapy in preterm infants with apnea of prematurity]. ( Lin, XZ; Xie, JB, 2022) |
| "Methylxanthine, including caffeine citrate and aminophylline, is the most common pharmacologic treatment for apnea of prematurity." | 9.22 | Comparative efficacy and safety of caffeine citrate and aminophylline in treating apnea of prematurity: A systematic review and meta-analysis. ( Jiang, H; Li, Y; Liu, W; Miao, Y; Wang, A; Zhang, Y; Zhao, S; Zhou, Y, 2022) |
| "To determine the half-life of serum caffeine concentrations and its relation to apnea of prematurity (AOP) after caffeine is discontinued in preparation for hospital discharge." | 9.22 | Apnea of prematurity and caffeine pharmacokinetics: potential impact on hospital discharge. ( Davidson, D; DeCristofaro, J; Demeglio, D; Doyle, J; Katz, S; Varela, M, 2016) |
| "Apnea remains one of the most concerning and prevalent respiratory disorders spanning all ages from infants (particularly those born preterm) to adults." | 9.05 | Mechanistic actions of oxygen and methylxanthines on respiratory neural control and for the treatment of neonatal apnea. ( MacFarlane, PM; Mitchell, L, 2020) |
| "Caffeine is widely used for the treatment of neonatal apnea, but there is no agreement on the optimum maintenance dose for preterm infants." | 8.98 | Efficacy and Safety of Different Maintenance Doses of Caffeine Citrate for Treatment of Apnea in Premature Infants: A Systematic Review and Meta-Analysis. ( Chen, J; Chen, X; Jin, L, 2018) |
| "The purpose of this paper is to verify whether the concentrations of caffeine in saliva are comparable to serum concentrations in preterm infants who are treated with caffeine for apnea of prematurity." | 8.12 | The association of salivary caffeine levels with serum concentrations in premature infants with apnea of prematurity. ( Andrés, JLP; Cañada-Martínez, AJ; García-Robles, A; González, PS; Pericás, CC; Ponce-Rodriguez, HD; Solaz-García, Á; Vento, M; Verdú-Andrés, J, 2022) |
| " Treatment of neonatal apnea with theophylline as documented by a normal follow-up pneumocardiogram should be considered successful only when the levels of both theophylline and caffeine have been documented subtherapeutic at time of re-test." | 7.66 | Effect of serum caffeine level on pneumocardiogram of premature infants treated for apnea with theophylline. ( Banagale, RC, 1982) |
| "Theophylline and caffeine are both effective stimulants of the central nervous system for the therapy of neonatal apnea." | 7.66 | Pharmacologic considerations in the therapy of neonatal apnea. ( Aranda, JV; Grondin, D; Sasyniuk, BI, 1981) |
| "The efficacy of caffeine citrate in the management of apnea in the newborn infant was evaluated." | 7.65 | Efficacy of caffeine in treatment of apnea in the low-birth-weight infant. ( Aranda, JV; Bergsteinsson, H; Gorman, W; Gunn, T, 1977) |
| "Caffeine treatment is routinely used in premature infants to prevent development of apnea and bronchopulmonary dysplasia." | 7.30 | Effects of Different Onset Times of Early Caffeine Treatment on Mesenteric Tissue Oxygenation and Necrotizing Enterocolitis: A Prospective, Randomized Study. ( Cakir, SC; Cetinkaya, M; Koksal, N; Ozkan, H; Saglam, O, 2023) |
| "Caffeine exposure was associated to SGA (OR = 1." | 5.51 | Caffeine exposure during pregnancy, small for gestational age birth and neonatal outcome - results from the Norwegian Mother and Child Cohort Study. ( Bellocco, R; Brantsæter, AL; Elfvin, A; Jacobsson, B; Meltzer, HM; Modzelewska, D; Sengpiel, V, 2019) |
| "Apnea of prematurity (AOP) is one of the common diseases in preterm infants." | 5.22 | [Recent research on gene polymorphisms related to caffeine therapy in preterm infants with apnea of prematurity]. ( Lin, XZ; Xie, JB, 2022) |
| "Methylxanthine, including caffeine citrate and aminophylline, is the most common pharmacologic treatment for apnea of prematurity." | 5.22 | Comparative efficacy and safety of caffeine citrate and aminophylline in treating apnea of prematurity: A systematic review and meta-analysis. ( Jiang, H; Li, Y; Liu, W; Miao, Y; Wang, A; Zhang, Y; Zhao, S; Zhou, Y, 2022) |
| "To determine the half-life of serum caffeine concentrations and its relation to apnea of prematurity (AOP) after caffeine is discontinued in preparation for hospital discharge." | 5.22 | Apnea of prematurity and caffeine pharmacokinetics: potential impact on hospital discharge. ( Davidson, D; DeCristofaro, J; Demeglio, D; Doyle, J; Katz, S; Varela, M, 2016) |
| "Apnea remains one of the most concerning and prevalent respiratory disorders spanning all ages from infants (particularly those born preterm) to adults." | 5.05 | Mechanistic actions of oxygen and methylxanthines on respiratory neural control and for the treatment of neonatal apnea. ( MacFarlane, PM; Mitchell, L, 2020) |
| "Caffeine is an effective treatment for apnea of prematurity and has several important benefits, including decreasing respiratory morbidity and motor impairment." | 5.05 | Caffeine for preterm infants: Fixed standard dose, adjustments for age or high dose? ( Patel, RM; Saroha, V, 2020) |
| "Caffeine is widely used for the treatment of neonatal apnea, but there is no agreement on the optimum maintenance dose for preterm infants." | 4.98 | Efficacy and Safety of Different Maintenance Doses of Caffeine Citrate for Treatment of Apnea in Premature Infants: A Systematic Review and Meta-Analysis. ( Chen, J; Chen, X; Jin, L, 2018) |
| "Corticosteroids, intramuscular vitamin A and caffeine reduce the risk of bronchopulmonary dysplasia (BPD) in very-low-birth-weight infants." | 4.84 | Evidence-based neonatal drug therapy for prevention of bronchopulmonary dysplasia in very-low-birth-weight infants. ( Kirpalani, H; Millar, D; Roberts, R; Schmidt, B, 2008) |
| "The purpose of this paper is to verify whether the concentrations of caffeine in saliva are comparable to serum concentrations in preterm infants who are treated with caffeine for apnea of prematurity." | 4.12 | The association of salivary caffeine levels with serum concentrations in premature infants with apnea of prematurity. ( Andrés, JLP; Cañada-Martínez, AJ; García-Robles, A; González, PS; Pericás, CC; Ponce-Rodriguez, HD; Solaz-García, Á; Vento, M; Verdú-Andrés, J, 2022) |
| "We studied the effects of intravenous administration of 20 mg/kg caffeine citrate on glucose homeostasis, cardiorespiratory status, and urinary excretion of catecholamines and electrolytes in 12 premature infants with recurrent apnea." | 3.66 | The metabolic effects of caffeine in the newborn infant. ( Maisels, MJ; Marks, KH; Rothberg, AD; Ward, RM, 1981) |
| " Treatment of neonatal apnea with theophylline as documented by a normal follow-up pneumocardiogram should be considered successful only when the levels of both theophylline and caffeine have been documented subtherapeutic at time of re-test." | 3.66 | Effect of serum caffeine level on pneumocardiogram of premature infants treated for apnea with theophylline. ( Banagale, RC, 1982) |
| "Theophylline and caffeine are both effective stimulants of the central nervous system for the therapy of neonatal apnea." | 3.66 | Pharmacologic considerations in the therapy of neonatal apnea. ( Aranda, JV; Grondin, D; Sasyniuk, BI, 1981) |
| " This view assumes that pharmacologic manipulation of apnea of prematurity is in itself a desirable goal and clearly superior to treatment of apneic episodes when they occur." | 3.66 | Adverse effects of caffeine and theophylline in the newborn infant. ( Aranda, JV; Clozel, M; Howell, J, 1981) |
| "The efficacy of caffeine citrate in the management of apnea in the newborn infant was evaluated." | 3.65 | Efficacy of caffeine in treatment of apnea in the low-birth-weight infant. ( Aranda, JV; Bergsteinsson, H; Gorman, W; Gunn, T, 1977) |
| "Caffeine treatment is routinely used in premature infants to prevent development of apnea and bronchopulmonary dysplasia." | 3.30 | Effects of Different Onset Times of Early Caffeine Treatment on Mesenteric Tissue Oxygenation and Necrotizing Enterocolitis: A Prospective, Randomized Study. ( Cakir, SC; Cetinkaya, M; Koksal, N; Ozkan, H; Saglam, O, 2023) |
| "Caffeine exposure was associated to SGA (OR = 1." | 1.51 | Caffeine exposure during pregnancy, small for gestational age birth and neonatal outcome - results from the Norwegian Mother and Child Cohort Study. ( Bellocco, R; Brantsæter, AL; Elfvin, A; Jacobsson, B; Meltzer, HM; Modzelewska, D; Sengpiel, V, 2019) |
| "The decision-making process for estimating the optimal dosage is critical in clinical settings." | 1.48 | Estimation of Caffeine Regimens: A Machine Learning Approach for Enhanced Clinical Decision Making at a Neonatal Intensive Care Unit (NICU). ( Shirwaikar, RD, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 21 (52.50) | 18.7374 |
| 1990's | 2 (5.00) | 18.2507 |
| 2000's | 3 (7.50) | 29.6817 |
| 2010's | 4 (10.00) | 24.3611 |
| 2020's | 10 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Xie, JB | 1 |
| Lin, XZ | 1 |
| Miao, Y | 1 |
| Zhou, Y | 1 |
| Zhao, S | 1 |
| Liu, W | 1 |
| Wang, A | 1 |
| Zhang, Y | 1 |
| Li, Y | 1 |
| Jiang, H | 1 |
| García-Robles, A | 1 |
| Solaz-García, Á | 1 |
| Verdú-Andrés, J | 1 |
| Andrés, JLP | 1 |
| Cañada-Martínez, AJ | 1 |
| Pericás, CC | 1 |
| Ponce-Rodriguez, HD | 1 |
| Vento, M | 1 |
| González, PS | 1 |
| Prakash, R | 1 |
| Schmidt, B | 2 |
| Mitchell, L | 1 |
| MacFarlane, PM | 1 |
| Saroha, V | 1 |
| Patel, RM | 1 |
| Ozkan, H | 1 |
| Cetinkaya, M | 1 |
| Cakir, SC | 1 |
| Saglam, O | 1 |
| Koksal, N | 1 |
| Jiang, Z | 1 |
| Gao, X | 1 |
| Liang, J | 1 |
| Ni, S | 1 |
| El-Dib, M | 1 |
| Szakmar, E | 1 |
| Chakkarapani, E | 1 |
| Aly, H | 1 |
| Shirwaikar, RD | 1 |
| Chen, J | 1 |
| Jin, L | 1 |
| Chen, X | 1 |
| Modzelewska, D | 1 |
| Bellocco, R | 1 |
| Elfvin, A | 1 |
| Brantsæter, AL | 1 |
| Meltzer, HM | 1 |
| Jacobsson, B | 1 |
| Sengpiel, V | 1 |
| Doyle, J | 1 |
| Davidson, D | 1 |
| Katz, S | 1 |
| Varela, M | 1 |
| Demeglio, D | 1 |
| DeCristofaro, J | 1 |
| Roberts, R | 1 |
| Millar, D | 1 |
| Kirpalani, H | 1 |
| BARRIE, H | 1 |
| COTTOM, D | 1 |
| WILSON, BD | 1 |
| OGUNI, S | 1 |
| Williams, FL | 1 |
| Ogston, SA | 1 |
| van Toor, H | 1 |
| Visser, TJ | 1 |
| Hume, R | 1 |
| Labow, R | 1 |
| Dandurand, KR | 1 |
| Frauch, P | 1 |
| van Pernis, MJ | 1 |
| Aranda, JV | 5 |
| Scalais, E | 1 |
| Papageorgiou, A | 1 |
| Beharry, K | 1 |
| Rothberg, AD | 1 |
| Marks, KH | 1 |
| Ward, RM | 1 |
| Maisels, MJ | 1 |
| Horowitz, DA | 1 |
| Jablonski, WJ | 1 |
| Mehta, KA | 1 |
| Banagale, RC | 1 |
| Grondin, D | 1 |
| Sasyniuk, BI | 1 |
| Turmen, T | 1 |
| Davis, J | 1 |
| Somani, SM | 1 |
| Khanna, NN | 1 |
| Howell, J | 1 |
| Clozel, M | 1 |
| Banner, W | 1 |
| Czajka, PA | 1 |
| Floberg, S | 1 |
| Lindström, B | 1 |
| Lönnerholm, G | 1 |
| Gressens, P | 1 |
| Mesples, B | 1 |
| Sahir, N | 1 |
| Marret, S | 1 |
| Sola, A | 1 |
| Gorman, W | 1 |
| Bergsteinsson, H | 1 |
| Gunn, T | 1 |
| Kulkarni, PB | 1 |
| Dorand, RD | 1 |
| Koppe, JG | 1 |
| de Bruijne, JI | 1 |
| de Boer, P | 1 |
| Martinet, Y | 1 |
| Debry, G | 1 |
| Stavric, B | 1 |
| Pagliara, AS | 1 |
| Karl, IE | 1 |
| Kipnis, DB | 1 |
| Schiff, D | 1 |
| Chan, G | 1 |
| Stern, L | 1 |
| Bulgarelli, R | 1 |
9 reviews available for caffeine and Infant, Newborn, Diseases
| Article | Year |
|---|---|
[Recent research on gene polymorphisms related to caffeine therapy in preterm infants with apnea of prematurity].
Topics: Apnea; Caffeine; Humans; Infant; Infant, Newborn; Infant, Newborn, Diseases; Infant, Premature; Infa | 2022 |
Comparative efficacy and safety of caffeine citrate and aminophylline in treating apnea of prematurity: A systematic review and meta-analysis.
Topics: Aminophylline; Apnea; Caffeine; Citrates; Humans; Infant; Infant, Newborn; Infant, Newborn, Diseases | 2022 |
Mechanistic actions of oxygen and methylxanthines on respiratory neural control and for the treatment of neonatal apnea.
Topics: Animals; Apnea; Caffeine; Continuous Positive Airway Pressure; Humans; Infant, Newborn; Infant, Newb | 2020 |
Caffeine for preterm infants: Fixed standard dose, adjustments for age or high dose?
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Cerebral Hemorrhage; Citrates; Dose-Response Relationsh | 2020 |
Challenges in respiratory management during therapeutic hypothermia for neonatal encephalopathy.
Topics: Brain; Caffeine; Humans; Hypothermia, Induced; Hypoxia-Ischemia, Brain; Infant; Infant, Newborn; Inf | 2021 |
Efficacy and Safety of Different Maintenance Doses of Caffeine Citrate for Treatment of Apnea in Premature Infants: A Systematic Review and Meta-Analysis.
Topics: Apnea; Caffeine; Citrates; Humans; Infant; Infant, Newborn; Infant, Newborn, Diseases; Infant, Prema | 2018 |
Evidence-based neonatal drug therapy for prevention of bronchopulmonary dysplasia in very-low-birth-weight infants.
Topics: Bronchopulmonary Dysplasia; Caffeine; Cerebral Palsy; Clinical Trials as Topic; Evidence-Based Medic | 2008 |
Environmental factors and disturbances of brain development.
Topics: Brain; Brain Injuries; Caffeine; Cocaine; Environmental Pollutants; Ethanol; Female; Humans; Infant, | 2001 |
An update on research with coffee/caffeine (1989-1990).
Topics: Animals; Antimutagenic Agents; Caffeine; Cholesterol; Coffee; Coronary Disease; Female; Humans; Infa | 1992 |
3 trials available for caffeine and Infant, Newborn, Diseases
| Article | Year |
|---|---|
Effects of Different Onset Times of Early Caffeine Treatment on Mesenteric Tissue Oxygenation and Necrotizing Enterocolitis: A Prospective, Randomized Study.
Topics: Birth Weight; Caffeine; Enterocolitis, Necrotizing; Female; Fetal Diseases; Humans; Infant; Infant, | 2023 |
Apnea of prematurity and caffeine pharmacokinetics: potential impact on hospital discharge.
Topics: Apnea; Caffeine; Drug Monitoring; Female; Gestational Age; Half-Life; Humans; Infant, Newborn; Infan | 2016 |
Effects of caffeine being studied for treatment of apnea in newborns.
Topics: Apnea; Caffeine; Clinical Trials as Topic; Double-Blind Method; Humans; Infant, Newborn; Infant, New | 1983 |
28 other studies available for caffeine and Infant, Newborn, Diseases
| Article | Year |
|---|---|
The association of salivary caffeine levels with serum concentrations in premature infants with apnea of prematurity.
Topics: Apnea; Caffeine; Humans; Infant; Infant, Newborn; Infant, Newborn, Diseases; Infant, Premature; Infa | 2022 |
It is time for a rethink about caffeine therapy for apnoea of prematurity.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; Infant, Newborn, Diseas | 2023 |
Caffeine for Apnea of Prematurity: Too Much or Too Little of a Good Thing.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; Infant, Newborn, Diseas | 2023 |
Simultaneous quantitation of serum caffeine and its metabolites by ultra-high-performance liquid chromatography-tandem mass spectrometry for CYP1A2 activity prediction in premature infants.
Topics: Apnea; Caffeine; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP1A2; Female; Humans; Infa | 2021 |
Estimation of Caffeine Regimens: A Machine Learning Approach for Enhanced Clinical Decision Making at a Neonatal Intensive Care Unit (NICU).
Topics: Caffeine; Clinical Decision-Making; Decision Making, Computer-Assisted; Decision Trees; Drug Dosage | 2018 |
Caffeine exposure during pregnancy, small for gestational age birth and neonatal outcome - results from the Norwegian Mother and Child Cohort Study.
Topics: Adult; Birth Weight; Caffeine; Cohort Studies; Female; Gestational Age; Humans; Infant, Low Birth We | 2019 |
Respiratory stimulants in the newborn.
Topics: Caffeine; Central Nervous System Stimulants; Humans; Infant; Infant, Newborn; Infant, Newborn, Disea | 1962 |
[DIAGNOSIS AND THERAPY OF RESPIRATORY DISORDERS IN THE NEWBORN].
Topics: Asphyxia Neonatorum; Caffeine; Cerebral Hemorrhage; Cyanosis; Diagnosis; Exchange Transfusion, Whole | 1963 |
Serum thyroid hormones in preterm infants: associations with postnatal illnesses and drug usage.
Topics: Aminophylline; Bacterial Infections; Caffeine; Dexamethasone; Dopamine; Heroin; Humans; Infant, Newb | 2005 |
Use of caffeine in neonates.
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Newborn, Diseases | 1984 |
Use of caffeine in neonates.
Topics: Caffeine; Humans; Infant, Newborn; Infant, Newborn, Diseases; Solubility | 1984 |
Ontogeny of human caffeine and theophylline metabolism.
Topics: Adult; Aged; Apnea; Caffeine; Child; Child, Preschool; Half-Life; Humans; Infant; Infant, Newborn; I | 1984 |
The metabolic effects of caffeine in the newborn infant.
Topics: Apnea; Blood Glucose; Caffeine; Catecholamines; Electrolytes; Heart Rate; Homeostasis; Humans; Infan | 1981 |
Apnea associated with theophylline withdrawal in a term neonate.
Topics: Apnea; Caffeine; Female; Humans; Infant, Newborn; Infant, Newborn, Diseases; Maternal-Fetal Exchange | 1982 |
Effect of serum caffeine level on pneumocardiogram of premature infants treated for apnea with theophylline.
Topics: Apnea; Caffeine; Electrocardiography; False Negative Reactions; Humans; Infant, Newborn; Infant, New | 1982 |
Pharmacologic considerations in the therapy of neonatal apnea.
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Newborn, Diseases; Monitoring, Physiologic; Theoph | 1981 |
Relationship of dose and plasma concentrations of caffeine and ventilation in neonatal apnea.
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Newborn, Diseases; Infant, Premature; Kinetics; Re | 1981 |
Methylxanthines in serum, saliva, and spinal fluid of premature infants.
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Newborn, Diseases; Infant, Premature; Kinetics; Sa | 1981 |
Adverse effects of caffeine and theophylline in the newborn infant.
Topics: Apnea; Asphyxia Neonatorum; Caffeine; Cardiovascular System; Central Nervous System; Digestive Syste | 1981 |
Acute caffeine overdose in the neonate.
Topics: Caffeine; Female; Humans; Infant, Newborn; Infant, Newborn, Diseases; Respiratory Insufficiency; Sei | 1980 |
Simultaneous determination of theophylline and caffeine after extractive alkylation in small volumes of plasma by gas chromatography--mass spectrometry.
Topics: Alkylation; Apnea; Caffeine; Gas Chromatography-Mass Spectrometry; Humans; Infant, Newborn; Infant, | 1980 |
Efficacy of caffeine in treatment of apnea in the low-birth-weight infant.
Topics: Apnea; Caffeine; Carbon Dioxide; Drug Evaluation; Humans; Hydrogen-Ion Concentration; Infant, Low Bi | 1977 |
Caffeine toxicity in a neonate .
Topics: Caffeine; Humans; Infant, Newborn; Infant, Newborn, Diseases; Male | 1979 |
Apneic spells and transcutaneous PO2: treatment with caffeine, 19-year follow-up.
Topics: Apnea; Blood Gas Analysis; Blood Pressure; Caffeine; Diagnosis, Differential; Follow-Up Studies; Hea | 1979 |
[Effects of coffee on the respiratory system].
Topics: Adult; Apnea; Bronchial Neoplasms; Caffeine; Coffee; Female; Humans; Infant, Newborn; Infant, Newbor | 1992 |
Transient neonatal diabetes: delayed maturation of the pancreatic beta cell.
Topics: Adenylyl Cyclases; Blood Glucose; Caffeine; Cyclic AMP; Diabetes Mellitus, Type 1; Female; Glucose T | 1973 |
Proceedings: Clinical implications of bilirubin-albumin binding in the newborn.
Topics: Age Factors; Benzoates; Bilirubin; Caffeine; Diazepam; Humans; Hyperbilirubinemia; Infant, Newborn; | 1973 |
[Iatrogenic damage in pediatrics].
Topics: Anti-Bacterial Agents; Bismuth; Caffeine; Child; Child, Preschool; Digitalis Glycosides; Diuretics; | 1971 |